Recommendation of the President – Voydeya (danicopan)
On 2 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 38/2025 on the appraisal Voydeya (danicopan) under drug program B.96 “Treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) (ICD-10 D59.5)”